VenoValve trial shows sustained patient benefits at 24 months

IRVINE, CA - enVVeno Medical (TASE:PMCN) Corporation (NASDAQ:NVNO), a medical device company with a market capitalization of $54.5 million, reported interim two-year follow-up data from its pivotal trial of the VenoValve, indicating sustained clinical improvement and patient benefit. According to InvestingPro analysis, the company maintains a "Fair" overall financial health score, with particularly strong liquidity metrics. The data, presented...